Excluded studies with reasons for exclusion. by Si He (3236646)

Subjects:

Subgroup Analysis of the Occurrence of the Primary Endpoint and Its Components. by Karl Ingard (22582091)

Subjects:

Flow diagram of the studies included in the meta-analysis. by Si He (3236646)

Subjects:

Cinnamaldehyde repellency test within 6 hours in parthenogenesis <i>H. longicornis.</i> by Ceyan Kuang (8554557)

Subjects:

Shares of antibiotic substances on total prescription in UTI treatment (N39.0, N30.0) by sex and age group in 2019 (female: n = 238.670 prescriptions; male: n = 40.641 prescription... by Thomas Hanslmeier (19949694)

Subjects: “…fluoroquinolone shares decreased…”

Shares of antibiotic substances on total prescription by quarter from 2013 to 2019 for female and male patients with UTI (N39.0, N30.0)(female: n = 1.681.255 prescriptions; male: n... by Thomas Hanslmeier (19949694)

Subjects: “…fluoroquinolone shares decreased…”

Shares of specialist groups prescribing 1^st, 2^nd, and 3^rd antibiotic prescriptions in UTI treatment of females (N39.0, N30.0) in 2018 and 2019. by Thomas Hanslmeier (19949694)

Subjects: “…fluoroquinolone shares decreased…”

Number of antibiotic prescriptions in female and male patients with UTI (N30.0 and/or N39.0). by Thomas Hanslmeier (19949694)

Subjects: “…fluoroquinolone shares decreased…”

Shares of antibiotic substances on total prescription in female patients with UTI (N39.0, N30.0) by physician specialties (GPs: n = 1.299.641 prescriptions; gynecologists n = 141.8... by Thomas Hanslmeier (19949694)

Subjects: “…fluoroquinolone shares decreased…”

Comparison of 1^st, 2^nd, and 3^rd antibiotic prescription. by Thomas Hanslmeier (19949694)

Subjects: “…fluoroquinolone shares decreased…”

UTI diagnoses by sex and physician specialty (2013–2019). by Thomas Hanslmeier (19949694)

Subjects: “…fluoroquinolone shares decreased…”

Quality of life and Beck Depression Inventory baseline and post CRT+MRT, CRT and RUHB. by Sergio R. Thomaz (20308465)

Subjects:

Cardiorespiratory variable measurement of the study population. by Sergio R. Thomaz (20308465)

Subjects:

Description of the myofascial release techniques. by Sergio R. Thomaz (20308465)

Subjects:

ΔQuality of life and ΔBeck Depression Inventory baseline and post CRT+MRT, CRT and RUHB. by Sergio R. Thomaz (20308465)

Subjects:

Study flow diagram. by Sergio R. Thomaz (20308465)

Subjects:

Changes in maximal strength within each group after treatment. by Sergio R. Thomaz (20308465)

Subjects:

ΔVO₂ (ml/min), ΔVO₂/HR and ΔVE/VCO₂ slope baseline and post CRT+MRT, CRT and RUHB. by Sergio R. Thomaz (20308465)

Subjects:

Clinical characteristics of the study population. by Sergio R. Thomaz (20308465)

Subjects:

Additional file 3 of Single-cell profiling reveals a reduced epithelial defense system, decreased immune responses and the immune regulatory roles of different fibroblast subpopula... by Lin Lin (46073)

“…P values were calculated via the two-sided Wilcoxon test. ns, not significant, **, P < 0.01 and ****, P < 0.0001. (G) Feature plot showing LDLR expression levels in C1Q+ macrophages between CAG and control samples.…”